Headache drug could soothe Allergan's pains

11 March 2019

Hoping to bounce back from a bad news week, Allergan (NYSE: AGN) has announced the US medicines regulator will review its application for its novel CGRP agonist ubrogepant.

Last year the firm announced positive data for the migraine therapy from the Phase III ACHIEVE II trial, with both doses showing a statistically-significant impact on pain freedom compared with placebo.

Allergan will hope to take a share of a new and potentially lucrative market for CGRP blockers, currently led by biologic options, which is rapidly becoming more crowded.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK